AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza…
Drug Manufacturers - General
GB, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -38.61 | 52.91 | 86.19 | |
| Graham Fair Price | 47.40 | 27.65 | 18.76 | |
| PEG | -90.74 | 0.20 | -2.20 | |
| Price/Book | 5.51 | 5.62 | 5.33 | |
| Price/Cash Flow | 60.55 | 216.94 | 135.12 | |
| Prices/Earnings | -55.50 | 24.13 | 54.24 | |
| Price/Sales | -1.27 | 16.66 | 16.88 | |
| Price/FCF | 60.55 | 216.94 | 135.12 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 3.59 | 0.75 | 0.73 | |
| Operating Margin | 139.48 | 0.26 | 0.11 | |
| ROA | 124.23 | 0.02 | < 0.005 | |
| ROE | 0.02 | 0.06 | 137.12 | |
| ROIC | 0.02 | 0.04 | 68.17 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.21 | < 0.005 | 106275.40 | |
| Dividends QOQ | -1.00 | 1515.50 | 151665.27 | |
| EBIT QOQ | -0.33 | 1.45 | 345.90 | |
| EPS QOQ | -0.25 | 1.19 | 380.65 | |
| FCF QOQ | -0.31 | -0.37 | -19.50 | |
| Revenue QOQ | 0.07 | 0.02 | -68.66 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 144.22 | 153.39 | 6.36 | |
| Days Sales Outstanding (DSO) | 86.94 | 87.10 | 0.19 | |
| Inventory Turnover | 0.62 | 0.59 | -5.98 | |
| Debt/Capitalization | 0.41 | 0.47 | 13.95 | |
| Quick Ratio | 0.59 | 0.70 | 19.55 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 25.23 | 24.16 | -4.27 | |
| Cash | 3.84 | 5.17 | 34.62 | |
| Capex | -0.62 | -1.03 | -65.67 | |
| Free Cash Flow | 1.00 | 0.63 | -37.09 | |
| Revenue | 7.97 | 8.15 | 2.31 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad